4//SEC Filing
Satvat Ali J. 4
Accession 0000899243-21-003647
CIK 0001731831other
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 7:08 PM ET
Size
11.4 KB
Accession
0000899243-21-003647
Insider Transaction Report
Form 4
Satvat Ali J.
Director10% Owner
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-01-26−21,528→ 0 totalExercise: $48.51Exp: 2030-05-27→ Common Stock (21,528 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-26−21,528→ 0 totalExercise: $30.87Exp: 2029-06-11→ Common Stock (21,528 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-26−43,056→ 0 totalExercise: $20.34Exp: 2028-06-30→ Common Stock (43,056 underlying)
Footnotes (3)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.
- [F2](Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
- [F3]The option was fully vested. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Documents
Issuer
Eidos Therapeutics, Inc.
CIK 0001731831
Entity typeother
Related Parties
1- filerCIK 0001621788
Filing Metadata
- Form type
- 4
- Filed
- Jan 27, 7:00 PM ET
- Accepted
- Jan 28, 7:08 PM ET
- Size
- 11.4 KB